Nortriptyline
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Nortriptyline: From Anxiety Disorder to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant, listed in the knowledge base for anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but about 11 relevant publications (including one randomized controlled trial and one Cochrane review) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder (from the knowledge graph; no approved indication text is available for the New Zealand licences) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L2 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology of the drug class, nortriptyline is a tricyclic antidepressant that mainly inhibits norepinephrine reuptake, with weaker serotonin reuptake inhibition. Pharmacology data compiled for this report show activity at the norepinephrine transporter (NET) and the serotonin transporter (SERT), as well as at the α1A-adrenoceptor and several inwardly rectifying potassium channels (Kir3.2, Kir3.4, Kir4.1).
Enhancing noradrenergic signalling in prefrontal circuits is the same pathway targeted by atomoxetine and other non-stimulant ADHD treatments. This offers a plausible mechanistic link between a drug used for mood and anxiety conditions and ADHD. A PET study in patients with depression also confirmed that nortriptyline occupies NET in the human brain.
The very high TxGNN score is a computational prediction and does not replace clinical evidence. A second predicted term, ADHD inattentive type (score 99.33%), is a subtype of the same condition. It has no specific trials or literature and largely mirrors the parent term, so it is not evaluated separately here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11052409 | 2000 | RCT | J Child Adolesc Psychopharmacol | Controlled study of nortriptyline's efficacy and tolerability in children and adolescents with ADHD |
| 25238582 | 2014 | Cochrane systematic review | Cochrane Database Syst Rev | Reviews tricyclic antidepressants as second-line treatment for ADHD in children and adolescents |
| 22700161 | 2012 | RCT (double-blind) | Pediatr Nephrol | Nortriptyline for enuresis in children with ADHD, assessing efficacy, tolerability and adverse effects |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Tricyclics, especially secondary amines such as nortriptyline, are established alternative ADHD treatments, but a narrow therapeutic index and cardiovascular toxicity limit use |
| 12270803 | 2002 | Review | Adolesc Med | Overview of ADHD medications in adolescents, including nortriptyline among the tricyclics |
| 8428873 | 1993 | Clinical study | J Am Acad Child Adolesc Psychiatry | Nortriptyline in children with ADHD and tic disorder or Tourette's syndrome |
| 8444763 | 1993 | Retrospective chart review | J Am Acad Child Adolesc Psychiatry | Chart review of 58 children and adolescents with ADHD treated with nortriptyline |
| 8444754 | 1993 | Retrospective study | J Am Acad Child Adolesc Psychiatry | Serum levels and ECG effects of nortriptyline in children and adolescents |
| 22303520 | 2012 | Guideline | Ann Clin Psychiatry | CANMAT recommendations for mood disorders with comorbid ADHD |
| 24345533 | 2014 | PET study | Int J Neuropsychopharmacol | Norepinephrine transporter occupancy by nortriptyline in patients with depression |
| 4075308 | 1985 | Early clinical report | Clin Neuropharmacol | Early report of nortriptyline in attention deficit disorder |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2710706 | Allegron | Tab 25 mg | Not available (cancelled) |
| 2710692 | Allegron | Tab 10 mg | Not available (cancelled) |
Both licences are cancelled, so no nortriptyline product currently holds a valid authorization in New Zealand.
Safety Considerations
- Contraindications (knowledge graph, not label text): Cardiac conditions (long QT syndrome, torsades de pointes, myocardial infarction, heart conduction disease, sudden cardiac arrest), liver failure, kidney failure, epilepsy, manic bipolar disorder, glaucoma, benign prostatic hyperplasia, substance abuse/dependence, stroke and cerebrovascular disorders, hyperthyroidism, and hemoglobinopathy.
- Cardiovascular risk: The literature notes a narrow therapeutic index and potential cardiovascular toxicity for tricyclics in ADHD, and ECG effects in children have been studied retrospectively.
- Pharmacological interactions: Activity at NET, SERT, the α1A-adrenoceptor and Kir channels was identified. No specific drug-drug interaction levels were reported.
Please refer to the package insert for full safety information, as label warnings and contraindications are not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: Published evidence (one pediatric RCT, a Cochrane review and several observational studies) supports a plausible role in ADHD, but no registered clinical trials exist, and tricyclic cardiovascular risk limits use. No nortriptyline product is currently authorized in New Zealand, and label safety data are missing.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- Review of the RCT and Cochrane data for effect size and cardiac safety, especially ECG monitoring
- Comparison against established ADHD treatments (stimulants, atomoxetine, α2-agonists)
- A regulatory pathway for supply, since all current licences are cancelled
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.